$LENZ

LENZ reported Q3 2026 earnings, highlighting 50% growth in product revenue and prescriptions. The company expanded its telehealth channel and national TV advertising, driving consumer demand. LENZ plans to reorganize, focusing on consumer marketing and reducing operating expenses by over 50%. CEO Eef Schimmelpennink will step down, with Dan Chevallard taking over as Interim CEO. Q3 product revenue was $2.6 million, with a 93% gross-to-net ratio.

HC Wainwright & Co. kept LENZ Therapeutics at Buy but reduced its price target to $16 from $38, a 57.9% cut. The new target suggests a 358.5% upside from the Oct 29 close of $3.49.

LENZ Therapeutics reported Q3 2026 revenue of $2.6M, up 50% sequentially, with 38,000 paid scripts. The company aims for $70M-$75M in 2027 operating expenses, targeting profitability by 2027. Telehealth channels show faster conversion and real-time ad monitoring. Cash reserves stand at $197.3M. Leadership transition is underway with Dan Chevillard as interim CEO.

TD Cowen kept its Buy rating on LENZ Therapeutics but reduced its price target to $45 from $50, citing a 10% decrease. This target suggests a 1301.9% upside from the Oct 28 close of $3.21, according to the firm.

LENZ Therapeutics' CEO Evert Schimmelpennink resigned, with Daniel Chevallard named interim CEO. Schimmelpennink's exit agreement includes $731,400 severance, a 2026 bonus, and COBRA premiums. Chevallard's interim salary is $650,000, with increased bonus targets and a $1.5M option award. Other executives also received retention packages.

LENZ Therapeutics reported Q3 sales of $2.6M for VIZZ, up 50% from Q2. CEO to step down; CFO to serve as interim. Q3 net loss was $31M. Company announced restructuring to cut 2027 expenses by 50%. Cash reserves at $197.3M. VIZZ has FDA approval and is seeking international approvals.

LENZ Therapeutics, Inc. (LENZ) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 LENZ Therapeutics Reports Third Quarter 2026 Financial Results, Announces Strategic Consumer Marketing Focused Reorganization and CEO Succession Q3 2026 VIZZ® product sales increased 50% over prior quarter, with strong momentum continuing into Q4 as consumer awarenes

TD Cowen kept a Buy rating and $50 price target on LENZ Therapeutics, implying a 1467.4% upside from its Oct 20 close. The analyst highlights the company's focus on the presbyopia market, with VIZZ showing positive clinical results and a strong safety profile.

LENZ Therapeutics' average stock price target was reduced from $25 to $22 by analysts, with a range of $7 to $60. This implies a 504% upside from the Oct. 9 closing price. The consensus rating remains 'Buy' among 7 analysts.

LENZ Therapeutics reported Q2 2026 revenue of $5.5M, with product revenue up 9% QoQ. Prescription growth surged 45% in July, driven by telehealth and advertising. Net loss was $31.9M, with $220M in cash reserves. The company highlighted strong patient persistence and global partnerships.